Another study showed that either silencing HMGA1 expression or mutation of a CK2 phosphorylation site—Serine 102—of HMGA1 enhanced efficacy of gefitinib in resistant NSCLC cells through reactivation of the downstream signaling of EGFR [75]. This evidence concerns the gene HMGA1 and non-small cell lung carcinoma.